https://www.selleckchem.com/products/kira6.html
0 months, p 0.001) had better overall survival rates. However, there was no difference in the prognosis between the cases treated with a targeted therapy (35.6 vs. non-targeted therapy 17.0 months, p = 0.211). None of the conventional regimens produced a better outcome. By multivariable analysis, immunotherapy (HR 0.28; 95% CI 0.11-0.74; P = 0.008) was found to be an independent prognostic factor for death. This study suggests that immunotherapy for patients with advanced IMA may provide favorable outcomes than other chemotherapy opt
Like
Comment
Share
